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Antiarrhythmic Effect of Reverse Ventricular
Remodeling Induced by Cardiac Resynchronization Therapy
The InSync ICD (Implantable Cardioverter-Defibrillator) Italian Registry
Luigi Di Biase, MD,*† Maurizio Gasparini, MD,‡ Maurizio Lunati, MD,§ Massimo Santini, MD,
Maurizio Landolina, MD,¶ Giuseppe Boriani, MD,# Antonio Curnis, MD,** Mario Bocchiardo, MD,††
Antonio Vincenti, MD,‡‡ Alessandra Denaro, MS,§§ Sergio Valsecchi, PHD,§§
Andrea Natale, MD,##¶¶ Luigi Padeletti, MD,*** on behalf of the InSync/InSync ICD Italian
Registry Investigators
Foggia, Rozzano, Milan, Rome, Pavia, Bologna, Brescia, Asti, Monza, and Florence, Italy;
Cleveland, Ohio; Austin, Texas; and Palo Alto, California
Objectives We investigated whether the reverse remodeling after cardiac resynchronization therapy (CRT) might reduce the
occurrence of ventricular arrhythmias (VAs).
Background It is currently debated whether CRT has an effect on the burden of VAs.
Methods The study included 398 patients treated with a CRT defibrillator and with a follow-up of at least 12 months.
Spontaneous VAs detected by the device were reviewed and validated.
Results A significant reduction in VA episodes and shock therapies was evident during the follow-up with greater de-
crease after 1 month. After 6 months of CRT, 227 patients (57%) showed a reduction in end-systolic volume of
10% and were defined as “responders.” The baseline characteristics were similar between the responders and
the nonresponders. Nonetheless, the proportion of patients with recurrence of VA after 1 month of CRT was sig-
nificantly lower in responders (32% vs. 43%, p  0.024). Among baseline variables no parameters emerged as
predictors of tachyarrhythmia recurrence. However, receiver-operating curve analysis recognized a reduction of
left ventricular end-systolic volume at 6 months of 13% as the best cutoff to identify the reduction of VAs (with a
sensitivity of 58% and a specificity of 54%).
Conclusions In patients treated with CRT defibrillators, a reduction in ventricular arrhythmic events occurs during the initial
12 months after implant and is correlated with the degree of ventricular remodeling induced by the therapy. Pa-
tients demonstrating reverse remodeling at midterm follow-up show a reduction in arrhythmias soon after the
implant, pronounced improvements at long-term, and a better survival. (J Am Coll Cardiol 2008;52:1442–9)
© 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2008.07.043s
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ccepted July 9, 2008.ystolic dysfunction, and ventricular dyssynchrony (1,2).
everal randomized trials have demonstrated that CRT
mproves symptoms, quality of life, and exercise capacity
3,4). In addition CRT has been shown to reduce hospital
tays, morbidity, and mortality risk especially in patients
mplanted with cardiac resynchronization therapy defibril-
ators (CRT-D) (5,6). Some studies have suggested that
RT is able to reduce inducibility and spontaneous occur-
ence of ventricular arrhythmias (VAs) and improve the
ppropriateness of implantable cardioverter-defibrillator
ICD) therapy (7–12). It has been postulated that the
ecrease in VAs might be associated with reverse LV
emodeling, thereby suggesting that reduced wall tension
ight result in fewer VAs (13). However, some studies have
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October 28, 2008:1442–9 CRT-D and Ventricular Arrhythmiashown that CRT can potentially promote VAs (14–16).
evertheless, controversy still exists as to whether CRT
ight affect sudden cardiac death by reducing the number
f lethal VAs in addition to its efficacy in decreasing
orsening HF mortality (17,18).
We hypothesized that CRT could affect the occurrence of
A as a result of the induced reverse LV remodeling. Thus, the
im of this study was to assess in a broader CRT population
he recurrence of VA and appropriate shock therapies at
ong-term follow-up and to evaluate their association with the
egree of improvement obtained with CRT.
ethods
rom 1999 to 2005, the InSync ICD Italian Registry prospec-
ively enrolled patients who underwent successful implantation
f CRT-D for primary or secondary prevention of sudden
eath and for resynchronization therapy. The registry included
atients with mild to severe symptomatic chronic HF (New
ork Heart Association [NYHA] functional class II to IV), a
eft ventricular ejection fraction (LVEF) 35%, and a wide
RS complex (130 ms).
All patients were receiving stable medical therapy including
eta-blocker drugs, angiotensin-converting enzyme inhibitors
r angiotensin receptor blocker drugs, and diuretics. Patients
ith a recent myocardial infarction or coronary revasculariza-
ion (3 months) or scheduled revascularization or with
ecompensated HF were excluded. All patients provided
ritten informed consent approved by each hospital’s ethics
ommittee.
Before device implantation, the following baseline demo-
raphic data were collected: medical history, clinical examina-
ion, history of ventricular tachycardias, syncope and/or cardiac
rrest, 12-lead electrocardiogram, NYHA functional class, and
tandard echocardiographic parameters. The latter included:
ssessment of left ventricular end-systolic diameter (LVESD),
eft ventricular end-diastolic diameter (LVEDD), left ventric-
lar end-diastolic volume (LVEDV), left ventricular end-
ystolic volume (LVESV), and LVEF assessed by Simpson’s
quation with the apical 4-chamber view (19) and evaluation of
he severity of mitral regurgitation with color Doppler in the
pical 4-chamber view. In addition, the interventricular me-
hanical delay (IVMD) was calculated as the time difference
etween the onset of the QRS duration and the opening of the
ortic and pulmonary valves.
All patients were implanted with Medtronic (Minneapolis,
innesota) CRT-D devices. All devices were triple-chamber
efibrillators capable of providing CRT and detecting and
reating ventricular tachyarrhythmias. Ventricular tachycardia
etection rate cutoff was requested to be at least 350 ms (171
eats/min) to avoid under-reporting of arrhythmic episodes.
ight-sided pacing leads were placed with standard tech-
iques. The LV lead was implanted transvenously via the
oronary sinus tributaries and placed preferably to stimulate the
ateral or posterolateral LV wall. DEchocardiography-guidedatrio-
entricular delay programming
as recommended to optimize
emodynamic function and was
erformed before discharge and
t follow-up. Adjustments of the
nterventricular (V-V) interval
ere not required.
Patients returned for regular
linic visits at 1, 3, and 6
onths and every 6 months
hereafter. Besides the clinical
valuation, 12-lead electrocardi-
gram, NYHA functional class,
nd detailed device checks were
erformed at each follow-up
isit. In addition, standard
chocardiography was per-
ormed at the 6- and 12-month
ollow-up visits in all patients.
chocardiographic recordings
ere analyzed in each center by
perators blinded to the ar-
hythmic episodes data re-
rieved by the ICD.
The impact of CRT on clinical and echocardiography
utcome was evaluated, comparing the baseline with 6- and
2-month follow-up data.
Spontaneous arrhythmic episodes detected by the device
ere validated by 2 independent electrophysiologists
linded to the patient outcome. If a consensus could not be
eached, a third electrophysiologist was involved in episode
eview.
To assess the recurrence of VA at long-term follow-up, we
ncluded in the analysis all patients with complete clinical and
evice data at the 12-month follow-up and we counted the
otal number of ventricular tachyarrhythmia episodes that
ccurred during the study and the number of patients experi-
ncing arrhythmias. The episodes considered in the analysis
ere all spontaneous ventricular tachyarrhythmias detected by
he implanted device and subsequently validated.
We assumed that CRT would result in progressive reverse
emodeling during follow-up. Thus, we counted ventricular
achycardias during the first month after implant as a measure
f the baseline patient arrhythmic status, and we assessed the
ecurrence of ventricular tachyarrhythmias in the period from
he second to the twelfth month to test the hypothesis of the
ntiarrhythmic effect of CRT secondary to the clinical and
chocardiographic improvement.
Moreover, we divided patients with and without evidence of
elevant LV remodeling after CRT (LVESV reduction10%)
20), and we estimated the incidence of arrhythmias in these
roups.
tatistical analysis. Continuous data were expressed as
eans SD. Categorical data were expressed by percentages.
Abbreviations
and Acronyms
CRT  cardiac
resynchronization therapy
HF  heart failure
ICD  implantable
cardioverter-defibrillator
IVMD  interventricular
mechanical delay
LV  left ventricle/
ventricular
LVEDD  left ventricular
end-diastolic diameter
LVEDV  left ventricular
end-diastolic volume
LVEF  left ventricular
ejection fraction
LVESD  left ventricular
end-systolic diameter
LVESV  left ventricular
end-systolic volume
NYHA  New York Heart
Association
VA  ventricular arrhythmiaifferences between mean data were compared by a t test for
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CRT-D and Ventricular Arrhythmias October 28, 2008:1442–9aussian variables and by the Mann-Whitney-Wilcoxon or
ilcoxon signed-rank nonparametric test for non-Gaussian
ariables, respectively, for independent or paired samples.
ormality of distributions was tested by the 1-sample
olmogorov-Smirnov test. Differences in proportions were
ompared by a chi-square analysis. Mortality rate was summa-
ized by construction of Kaplan-Meier curves, and the distri-
utions of the groups were compared by a log-rank test.
Univariable Cox regression analysis was used for the analysis
f predictors of tachyarrhythmia recurrence. All variables
ssociated with a p value 0.1 at univariable analysis were
ntered into the multivariable Cox regression analysis.
Receiver-operating characteristic (ROC) curve analysis was
pplied to assess the optimal cutoff value of the variables. In our
nalysis, we optimized sensitivity and specificity simulta-
eously; that is, we considered as an optimal cut-off the value
esulting in the maximum product of sensitivity and specificity
n the ROC curve.
A p value 0.05 was considered significant for all tests. All
tatistical analyses were performed with SPSS software (version
2.0, SPSS Inc., Chicago, Illinois).
esults
haracteristics and outcome of the study population. Three
undred ninety-eight patients were enrolled in the InSync
CD Italian Registry and had complete clinical and device data
t the 12-month follow-up. Of these, 175 received CRT-D for
rimary prevention and 223 for secondary prevention of
udden cardiac death. For the secondary prevention patients,
0 (27%) were cardiac arrest survivors, 94 (42%) had a history
f spontaneous sustained ventricular tachycardia, and 69 (31%)
ad a history of syncope associated with spontaneous ventric-
lar tachycardia or syncope of unknown origin with inducible
entricular tachyarrhythmia. The primary cause of HF was
oronary artery disease (67% of patients) with, frequently, a
ast history of myocardial infarction and of prior coronary
evascularization. Baseline clinical and echocardiographic char-
cteristics of the study population are given in Table 1. The
harmacological treatment was optimized at post-implant
ischarge visit (Table 1) and remained stable during follow-up.
Improvements in NYHA functional class and echocardio-
raphic parameters after 6 and 12 months of CRT are
ummarized in Table 2. At the 6-month follow-up, a signifi-
ant improvement in the clinical and echocardiographic pa-
ameters was observed in the overall population. The NYHA
unctional class improved (p 0.001) together with a decrease
n QRS duration (p 0.001). A significant increase in LVEF
p  0.001) and significant reduction of both LVEDD (p 
.039) and LVESD (p  0.048) occurred.
The LVEDV and LVESV were reduced at the 6-month
ollow-up (p  0.046 and p  0.004, respectively). Baseline
entricular dyssynchrony, assessed by IVMD, also decreased
p  0.010). The severity of mitral regurgitation was also
ignificantly decreased (p  0.006). All of these changes
emained stable at the 12-month follow-up visit. vWith a reduction in LVESV of 10% as cutoff value to
efine patients with clinically relevant LV reverse remodel-
ng after CRT, we identified 227 “responders” (57%) and
71 “nonresponders” (43%).
The baseline characteristics including medical history and
chocardiographic data were similar between groups, except for
higher percentage of ischemic patients among nonresponders
Table 1).
The implantation site of the LV lead was the lateral or
osterolateral wall in 191 responders (84%) and 147 non-
esponders (86%, p  0.615). The atrioventricular delay
ptimization was performed before discharge in 166 re-
ponders (73%) and 130 nonresponders (76%, p  0.512).
At baseline, 27 patients (12%) among responders and 16
mong nonresponders (9%, p  0.420) had history of docu-
ented paroxysmal or persistent forms of atrial fibrillation.
uring follow-up, episodes of device-detected atrial fibrillation
ere reported in 73 patients (32%) in the responder group and
1 patients (24%) in the nonresponder group (p 0.074). The
verall percentage of biventricular pacing during follow-up was
imilar between groups (96  5% vs. 95  4%, p  0.362) as
ell as the number of patients with a percentage of biventricular
acing higher than 85% (216 [95%] vs. 164 [96%], p  0.721).
During follow-up, both groups demonstrated a signifi-
ant reduction in QRS duration and NYHA functional class
t 6 months (all p  0.001), which was sustained at 12
onths (Table 2). For nonresponder patients, echocardio-
raphic parameters did not change significantly either at 6
r 12 months, whereas responder patients demonstrated a
ignificant reduction in LV dimensions and volumes at 6
onths (all p  0.02), together with a decrease of IVMD
p  0.006) and mitral regurgitation (p  0.003) that were
aintained at 12 months.
We extended the patient follow-up beyond 12 months
nd collected the survival status for all patients. The total
ean follow-up duration was 23  10 months and was
omparable in the 2 groups (24 11 months for responders
nd 23  9 months for nonresponders, p  0.207). A total
f 12 deaths occurred in the overall population: 4 in
he responder group (2 nonsudden cardiac, 2 noncardiac)
nd 8 in the nonresponder group (6 nonsudden cardiac, 2
oncardiac).
Kaplan-Meier event-free survival analysis demonstrated
hat the responder group had a significantly lower rate of
ll-cause mortality (p  0.042) (Fig. 1).
entricular tachyarrhythmias during follow-up. For the
ntire cohort, the programmed mean cycle length cutoff for
he detection of ventricular tachycardia was 395  29 ms,
hich needed to be sustained for 16 consequence beats. A
entricular fibrillation episode was detected if the cycle
ength was shorter than a mean of 313  14 ms and
ustained for 12 of 16 beats.
During 12 months of follow-up, spontaneous tachyar-
hythmia episodes detected by the device as ventricular
achycardia or fibrillation and confirmed by subsequent
alidation occurred in 163 of 398 patients (41%) of the
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October 28, 2008:1442–9 CRT-D and Ventricular Arrhythmiashole population. Overall, 986 arrhythmic episodes oc-
urred during the first 12 months; 354 of these were treated
ith shock therapy and the remaining with anti-tachycardia
acing, according to the device programming. The distri-
ution of tachyarrhythmias and shock therapies in the first
2 months is shown in Figure 2. In general, a significant
eduction in detected ventricular tachyarrhythmia episodes
nd shock therapies was evident during the follow-up with
reater decrease after 1 month.
We observed a similar incidence of ventricular tachyar-
hythmias in the 2 groups of primary (70 of 175 patients
emographic Data, Baseline Clinical Parameters,nd Pharma ological Tr atment of the Overall Population and the 2
Table 1 Demographic Data, Baseline Clinical Parameters,and Pharmacological Treatment of the Overall Populat
Parameter Total (n  398)
Male gender 349 (88)
Age, yrs 66 9
Ischemic etiology 266 (67)
Myocardial infarction 211 (53)
Previous CABG or angiography 144 (36)
Valvular disease 50 (13)
Secondary prevention 223 (56)
Hospital stays for HF (prior 12 months), n/yr 1.4 1.4
QRS duration, ms 166 31
Left bundle branch block 273 (69)
NYHA functional class 2.9 0.6
LVEF, % 26 7
LVEDD, mm 70 9
LVESD, mm 59 10
LVEDV, ml 247 91
LVESV, ml 178 79
IVMD, ms 39 25
Mitral regurgitation, degree 2.2 0.9
Spironolactone use
At enrollment 203 (51)
At post-implant discharge 213 (54)
Diuretic use 357 (90)
At enrollment
At post-implant discharge 368 (92)
ACE inhibitors or ARB use
At enrollment 303 (76)
At post-implant discharge 320 (80)
Beta-blocker use
At enrollment 221 (56)
At post-implant discharge 240 (60)
Digoxin use
At enrollment 159 (40)
At post-implant discharge 161 (40)
Class III antiarrhythmics use
At enrollment 154 (39)
At post-implant discharge 158 (40)
Nitrates use
At enrollment 78 (20)
At post-implant discharge 78 (20)
alues are presented as n (%) or mean  SD. The p values were determined on the basis of unpa
ACE  angiotensin-converting enzyme; ARB  angiotensin receptor blocker; CABG  coronar
entricular end-diastolic diameter; LVEDV left ventricular end-diastolic volume; LVEF left ventric
olume; NYHA  New York Heart Association.40%]) and secondary prevention patients (93 of 223 pa- rients [42%], p  0.732) and comparable trends of reduced
achyarrhythmias (Fig. 3).
Both with univariate and multivariate Cox regression anal-
sis, no parameters emerged as predictors of tachyarrhythmia
ecurrence among baseline clinical, echocardiographic, and
edication status variables.
V reverse remodeling and recurrence of ventricular
achyarrhythmias. During the 12months of follow-up, 85 of
27 (37%) responders experienced tachyarrhythmias, com-
ared with 78 of 171 (46%) nonresponders (p  0.101). In
articular, arrhythmic episodes were detected in 31 (14%)
groups
d the 2 Subgroups
sponders (n  227) Nonresponders (n  171) p Value
193 (85) 156 (91) 0.062*
66 9 66 9 0.978
142 (63) 124 (73) 0.037*
114 (50) 97 (57) 0.198*
75 (33) 69 (40) 0.133*
27 (12) 23 (13) 0.643*
121 (53) 102 (60) 0.207*
1.5 1.5 1.2 1.1 0.166
167 31 165 31 0.493
154 (68) 119 (70) 0.710*
3.0 0.6 2.8 0.6 0.123
26 6 27 8 0.095
70 8 71 10 0.471
59 8 59 12 0.816
249 92 242 90 0.737
189 75 164 83 0.200
44 23 32 29 0.248†
2.1 1.0 2.2 0.9 0.828
109 (48) 94 (55) 0.170*
115 (51) 98 (57) 0.188*
204 (90) 153 (89) 0.898*
210 (93) 158 (92) 0.966*
177 (78) 126 (74) 0.320*
187 (82) 133 (78) 0.252*
129 (57) 92 (54) 0.547*
141 (62) 99 (58) 0.394*
94 (41) 65 (38) 0.493*
94 (41) 67 (39) 0.654*
83 (37) 71 (42) 0.315*
85 (37) 73 (43) 0.290*
47 (21) 31 (18) 0.522*
47 (21) 31 (18) 0.522*
est except for: *chi-square analysis and †Mann-Whitney nonparametric test.
y bypass grafting; HF  heart failure; IVMD  interventricular mechanical delay; LVEDD  left
ction fraction; LVESD left ventricular end-systolic diameter; LVESV left ventricular end-systolicSub
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CRT-D and Ventricular Arrhythmias October 28, 2008:1442–9he first month and in 72 (32%) responders and 73 (43%)
onresponders (p  0.024) in the period from the second to
he twelfth month of follow-up.
The distribution of tachyarrhythmias in the first 12 months
or the 2 groups is shown in Figure 4. A significant reduction
n detected ventricular tachyarrhythmia episodes was evident
rom the second month only for responder patients.
On the basis of the ROC curve analysis of the total
opulation, a reduction of LVESV at 6 months of 13% was
ecognized as the best cutoff to identify the reduction of
achyarrhythmias (area under the curve 0.59; 95% confidence
nterval: 0.53 to 0.65). There were 200 patients with a
eduction of LVESV13%, and with this cutoff, we obtained
sensitivity of 58% and a specificity of 54%. With the a priori
efined cutoff of 10% for LVESV reduction, both the sensi-
ivity and the specificity were 54%.
iscussion
ur results show that in patients treated with CRT, a
eduction of the number of ventricular tachyarrhythmia
Figure 1 Survival Analysis
Kaplan-Meier estimates of time to death from
any cause in the responder and the nonresponder groups.
linical and Echocardiographic Parameters at Baseline and 6- and
Table 2 Clinical and Echocardiographic Parameters at Baseline
Baseline
Parameter
Total
(n  398)
Responders
(n  227)
Nonresponders
(n  171)
Tota
(n  39
QRS duration, ms 166 31 167 31 165 31 138 4
NYHA functional class 2.9 0.6 3.0 0.6 2.8 0.6 2.1 0
LVEF, % 26 7 26 6 27 8 32 1
LVEDD, mm 70 9 70 8 71 10 67 1
LVESD, mm 59 10 59 8 59 12 55 1
LVEDV, ml 247 91 249 92 242 90 203 8
LVESV, ml 178 79 189 75 164 83 137 6
IVMD, ms 39 25 44 23 32 29 17 2
Mitral regurgitation,
degree
2.2 0.9 2.1 1.0 2.2 0.9 1.8 0
p  0.05 versus baseline on the basis of paired t test; †p  0.05 versus responders; ‡p  0.05
Abbreviations as in Table 1.fpisodes and appropriate shock therapies occurred during
ollow-up both in terms of total number of events and
umber of patients with episodes. Moreover, the reduction
f tachycardias is associated with the reverse remodeling
nduced by the therapy. We observed an association be-
ween the remission of arrhythmic episodes during
ollow-up and the improvement of echocardiography pa-
ameters after CRT.
atient subgroups. Previous studies demonstrated that
RT results in progressive reverse remodeling during the first
onths after implant. In our study, at the 6-month follow-up
he overall population seemed to have both clinical and
chocardiography improvements. The significant reduction in
VEDV and LVESV that were evident after 6 months
ersisted to 12-month follow-up, as already reported in pub-
ished reports (21), and were associated with a better survival
fter the 12-month visit, confirming the findings of Yu et al. (20).
Our hypothesis was that the reverse remodeling induced by
RT could affect the occurrence of VAs. Thus, we sorted
atients into 2 groups: patients with and without evidence of
elevant LV remodeling after CRT, as measured by a decrease
f LVESV 10% at 6-month follow-up (20).
No baseline variable distinguished the groups, with the
xception of a higher incidence of ischemic etiology among the
onresponders. This finding supports previous results showing
arger improvements after CRT in patients with nonischemic
tiology (21) and, at the same time, confirms the lack of strong
aseline predictors of response to CRT among the baseline
linical and echocardiographic variables (22).
The arrhythmic status at the time of CRT implant was
imilar: the prevalence of secondary prevention indications as
ell as the incidence of arrhythmic episodes in the first month
f follow-up was comparable between groups. Nonetheless, the
roportion of patients with recurrence of VA after 1 month of
RT was significantly lower among those with evidence of
elevant LV remodeling. In particular, in this group the
ignificant reduction in detected ventricular tachyarrhythmia
pisodes was evident starting from the second month of
onth Follow-Up
6- and 12-Month Follow-Up
-Month Follow-Up 12-Month Follow-Up
Responders
(n  227)
Nonresponders
(n  171)
Total
(n  398)
Responders
(n  227)
Nonresponders
(n  171)
136 46* 141 44* 146 29* 144 30* 148 28*
1.9 0.6* 2.3 0.7*† 2.1 0.6* 1.9 0.6* 2.3 0.7*†
35 10* 27 9† 33 11* 36 11* 29 10†
65 10* 70 9† 67 10* 65 10* 69 9†
53 12* 59 11† 56 12* 53 12* 59 11†
195 78* 216 85† 200 79* 194 80* 211 77†
126 61* 153 67† 134 64* 126 65* 146 62†
14 19‡ 19 21 17 18‡ 16 20‡ 17 16
1.6 0.7* 2.1 0.9† 1.8 0.8* 1.6 0.7* 2.1 0.9†
baseline on the basis of Wilcoxon nonparametric test.12-M
and
6
l
8)
5*
.7*
0*
0*
2*
1*
5*
0‡
.8*ollow-up.
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October 28, 2008:1442–9 CRT-D and Ventricular ArrhythmiasYu et al. (20) demonstrated that the change in LV volume,
pecifically the reduction of LVESV, is a strong predictor of
esponse and survival after CRT implant. In the present study,
or the first time we showed that LVESV improvement is also
ssociated with a reduction in VAs.
This study demonstrates that CRT reduces the burden of
As and consequently the incidence of defibrillator discharges.
he expected reduction of VA burden could influence the
ecision to implant a CRT system alone or a CRT system
ssociated with ICD.However, the data from this study do not
olve the issue of whether CRT pacing alone without ICD
herapy is sufficient in this patient population for several
easons.
In our analysis no parameters emerged as predictors of
achyarrhythmia recurrence among baseline clinical, echocar-
iographic, and medication status variables. Therefore, subse-
uent reduction of VAs seems to be not predictable at the time
f the implant.
Similarly, as shown by our data and by several contradictory
Figure 2 Distribution of Tachyarrhythmias and Shock Therapies
(A) Number of patients with episodes, and distribution of ventricular tachyarrhythm
(B) Trend of shock therapies delivered and patients with shock during the observanvestigations on the refinement of selection criteria for CRT a22), reverse remodeling itself cannot be identified before
evice implantation.
Moreover, we observed that the sensitivity value for predic-
ion of tachyarrhythmia recurrence was 60% at ROC curve
nalysis and that the response to CRT seemed to reduce but
ot to eliminate the recurrence of VA. Thus, the occurrence of
single life-threatening arrhythmic episode, possibly treatable
y an ICD discharge, cannot be excluded.
revious studies. Several reports describe the potential
roarrhythmic or antiarrhythymic effect of CRT (7–17). In-
ersion of depolarization and repolarization occurring during
V and biventricular pacing and the dispersion of refractori-
ess has been evaluated (23). Under normal physiologic con-
itions, depolarization proceeds from the endocardium across
he ventricular wall to the epicardium with repolarization
ccurring in the opposite direction. During epicardial pacing
he sequence is altered, potentially contributing to either the
evelopment or suppression of VA. It is unknown whether
estoring synchrony leads to normalization of these changes
sodes occurring during the 12 months after implant.
eriod. *p  0.05 versus month 1, on the basis of chi-square analysis.ia epi
tion pnd whether mechanical remodeling is a prerequisite.
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CRT-D and Ventricular Arrhythmias October 28, 2008:1442–9Some studies have demonstrated that chronic biventricular
acing might reduce ICD therapy and the inducibility of
entricular tachycardia (7–10). However, all of these studies
ncluded a small number of patients.
Recently, McSwain et al. (17) retrospectively analyzed
ata from MIRACLE (Multicenter InSync Randomized
linical Evaluation) ICD and Contak-CD (Guidant Cor-
oration, Indianapolis, Indiana) trials. In this combined
opulation, CRT was not associated with a measurable
hange in the incidence of VAs. As reported by Ermis et al.
8), the absence of CRT-associated antiarrhythmic benefit
n these trials might be due to the fact that the treatment
ffect was examined in parallel patient populations rather
han within the same individuals. Moreover, the follow-up
Figure 3 Primary and Secondary Prevention Patients
Number of patients with episodes of ventricular arrhythmia during the 12 months
primary and secondary prevention groups. *p  0.05 versus month 1, on the bas
Figure 4 Responder and Nonresponder Patients
Number of patients with episodes of ventricular arrhythmia during the 12 months
in responder and nonresponder groups. *p  0.05 versus month 1, on the basisuration of these trials was 6 months, whereas, as in our
tudy, the reduction of ventricular tachyarrhythmia can take
lace during the first 12 months after implantation.
Additional indirect evidence of the effect of CRT on
rrhythmic status comes from the extension phase of the
ARE-HF (Cardiac Resynchronization-Heart Failure)
rial (24). Cleland et al. (24) observed a reduction of sudden
eath in the CRT arm that became evident late in the study
nd hypothesized that it could be potentially dependent on
mprovements in cardiac function and beneficial ventricular
emodeling.
tudy limitations. The main limitation of the study is the
ack of a randomization. However, it is difficult to address this
ssue in a randomized study. Programming of ICD therapy did
plant in
hi-square analysis.
plant
square analysis.after im
is of cafter im
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October 28, 2008:1442–9 CRT-D and Ventricular Arrhythmiasot follow a pre-defined protocol. However, it is unlikely that
evice programming influenced arrhythmic events.
Antiarrhythmic drugs can be considered a potential bias in
he arrhythmic recurrence. However, antiarrhythmic drugs
ere given to a similar proportion of patients in both groups.
Finally, the collection of echocardiographic parameters by
ocal operators and the lack of a central validation might
epresent a bias.
onclusions
o our knowledge, this is the first large prospective study
escribing VA recurrence at long-term follow-up in CRT-D
atients, with objective data resulting from ICD interroga-
ions. In patients treated with CRT, a reduction in ventricular
rrhythmic events occurs during the initial 12 months after
mplant and correlates with the degree of ventricular remod-
ling induced by the therapy, as measured by decrease in LV
olumes. Patients demonstrating significant reverse remodel-
ng at midterm follow-up might show a reduction in VAs soon
fter the implant, pronounced improvements at long-term, and
better survival.
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